CURR Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (8 rugp. 2023 @ 22:04):

Stats
Šios dienos apimtis	1 250.00
Vidutinė apimtis	17 656.00
Rinkos kapitalizacija	8.21M
EPS	$-0.0308 ( 2023-09-29 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.523
ATR14	$0.0330 (30.00%)

Insider Trading

Date	Person	Action	Amount	type
2022-09-23	Salkind Gene Z	Buy	117 647	Common Stock
2021-09-23	Salkind Gene Z	Buy	117 647	Restricted Stock Unit
2023-08-17	Salkind Gene Z	Buy	186 364	Restricted Stock Unit
2023-08-17	Bagg Gerald	Buy	186 364	Restricted Stock Unit
2023-08-17	Costantino Robert J	Buy	186 364	Restricted Stock Unit

INSIDER POWER
100.00
Last 90 transactions
Buy: 9 233 498 \| Sell: 208 150

Tūris Koreliacija

Ilgas: 0.25 (neutral)

Trumpas: -0.43 (neutral)

Signal:(51.795) Neutral

CURE Pharmaceutical Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

CURE Pharmaceutical Koreliacija - Valiuta/Žaliavos

-0.46
( neutral )

-0.44
( neutral )

0.00
( neutral )

-0.68
( moderate negative )

-0.04
( neutral )

0.52
( weak )

CURE Pharmaceutical Finansinės ataskaitos

Annual	2022
Pajamos:	$4.90M
Bruto pelnas:	$3.34M (68.20 %)
EPS:	$-0.0912

FY	2022
Pajamos:	$4.90M
Bruto pelnas:	$3.34M (68.20 %)
EPS:	$-0.0912

FY	2021
Pajamos:	$6.56M
Bruto pelnas:	$4.38M (66.85 %)
EPS:	$-0.260

FY	2020
Pajamos:	$2.05M
Bruto pelnas:	$975 000 (47.54 %)
EPS:	$-0.650

Financial Reports:

No articles found.

CURE Pharmaceutical

CURE Pharmaceutical Holding Corp., a biopharmaceutical company, focuses on the development and manufacturing of drug formulation and drug delivery technologies to enhance drug safety, efficacy, and patient adherence. It operates through two segments, Cure and Sera Labs. The company's pharmaceutical drug programs include CUREfilm Blue, a sildenafil oral thin film (OTF) for the treatment of erectile dysfunction; CUREfilm Canna, a cannabinoid product with optimized pharmacokinetic profiles using microCURE and CUREfilm technology; CUREfilm Anti-Viral, an orally bio-available anti-viral of an existing therapeutic leveraging existing pre-clinical/clinical safety and toxicity data; and CUREfilm Central Nervous System, a novel dosage form to treat mental health disorders, such as depression, PTSD, addiction disorders, obsessive compulsive disorders, and anxiety. It also sells various wellness products under its distribution partners' brands. In addition, the company develops 50,000IU and Vitamin D3 OTF for oral administration. It has a licensing agreement with Canopy Growth Corporation. The company was founded in 2011 and is headquartered in Oxnard, California.